Compare CMT & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMT | CRBP |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | 1570 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.4M | 134.8M |
| IPO Year | 1996 | 2014 |
| Metric | CMT | CRBP |
|---|---|---|
| Price | $19.69 | $8.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $46.17 |
| AVG Volume (30 Days) | 16.7K | ★ 145.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.31 |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $284,290,000.00 | $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.66 | $220.00 |
| P/E Ratio | $19.83 | ★ N/A |
| Revenue Growth | 5.49 | ★ 97.62 |
| 52 Week Low | $12.25 | $4.64 |
| 52 Week High | $22.29 | $20.56 |
| Indicator | CMT | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 56.25 |
| Support Level | $17.81 | $8.39 |
| Resistance Level | $19.80 | $8.43 |
| Average True Range (ATR) | 0.77 | 0.48 |
| MACD | -0.04 | 0.13 |
| Stochastic Oscillator | 70.90 | 79.61 |
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.